3 Pharma Brand, Fermentation Ingredient Maker and Hotels-to-Foods Group Stocks With a Strong Future Roadmap: Alkem Laboratories, Concord Biotech and ITC
- October 19, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Alkem Rs 5,050.00, P/E 28.43. Concord Biotech Rs 1,339.00, P/E 51.00. ITC Rs 263.50, P/E 15.77. Closing prices of 14 Oct 2026.
Quick Answer
Pharma brand, fermentation ingredient maker and hotels-to-foods group stocks with the clearest long-term roadmaps today include Alkem in branded generics in India along with generic exports and a presence in international markets, Concord Biotech in fermentation-based active ingredients, including immunosuppressants and anti-infectives and ITC in cigarettes, packaged foods, personal care, paperboards, hotels and agri products. P/E stands at 28.43 for Alkem (industry 37.59), 51.00 for Concord Biotech (industry 37.59) and 15.77 for ITC (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Pharma brand, fermentation ingredient maker and hotels-to-foods group stocks give investors exposure to medicines, drug ingredients and consumer goods sold across markets. Volumes, pricing and margins decide how much of that demand turns into profit.
This list covers three pharma brand, fermentation ingredient maker and hotels-to-foods group stocks: Alkem Laboratories for branded generics in India along with generic exports and a presence in international markets, Concord Biotech for fermentation-based active ingredients, including immunosuppressants and anti-infectives and ITC for cigarettes, packaged foods, personal care, paperboards, hotels and agri products. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma Brand, Fermentation Ingredient Maker and Hotels-To-Foods Group Stocks?
Pharma brand, fermentation ingredient maker and hotels-to-foods group stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Pharma Brand, Fermentation Ingredient Maker and Hotels-To-Foods Group Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three pharma brand, fermentation ingredient maker and hotels-to-foods group stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Alkem Laboratories | 5,050.00 | 62,663 | 28.43 | 37.59 | 16.66% | 0.15 |
| Concord Biotech | 1,339.00 | 13,913 | 51.00 | 37.59 | 12.94% | 0.00 |
| ITC | 263.50 | 318,338 | 15.77 | 34.85 | 28.53% | 0.03 |
Among healthcare and consumer stocks, Concord Biotech trades at a premium to the industry P/E, while Alkem and ITC trade at a discount.
Why Do Pharma Brand, Fermentation Ingredient Maker and Hotels-To-Foods Group Stocks Have a Strong Roadmap in India?
Pharma brand, fermentation ingredient maker and hotels-to-foods group stocks have a strong roadmap in India because branded medicine demand, drug ingredient orders and wider consumer brand reach keep adding volumes for these firms. Three drivers stand out.
- Branded medicines: Doctors prescribe trusted generic brands.
- Ingredient demand: Drug makers buy fermentation-based ingredients.
- Brand spread: Packaged foods and personal care reach more homes.
Alkem Laboratories: Domestic Brands and Generics Drive the Pipeline
Alkem’s roadmap rests on branded generics in India along with generic exports and a presence in international markets, with a mix of domestic brands and exports supporting earnings.
Revenue grew from Rs 10,796.84 crore in FY22 to Rs 15,295.62 crore in FY26, a 41.7% rise, and FY26 revenue was 13.7% higher than FY25. FY26 net profit rose 6.2% to Rs 2,353.13 crore. Over four years, net profit rose from Rs 1,680.32 crore in FY22 to Rs 2,353.13 crore. In Q1 FY27, revenue grew 11.0% to Rs 3,892.90 crore. Operating margin was 23.20% in FY26.
Debt to equity is 0.15 and return on equity is 16.66%. FY26 operating cash flow was Rs 1,963.03 crore against capital expenditure of Rs 617.26 crore. Alkem paid a dividend of Rs 53 per share for FY26, a yield of 1.01%. At a P/E of 28.43 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: The P/E of 28.43 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Concord Biotech: Fermentation Ingredients Drive the Pipeline
Concord Biotech’s roadmap rests on fermentation-based active ingredients, including immunosuppressants and anti-infectives, with regulated market exports supporting revenue.
Revenue grew from Rs 736.35 crore in FY22 to Rs 1,107.25 crore in FY26, a 50.4% rise. FY26 net profit was Rs 259.23 crore. In Q1 FY27, revenue grew 24.2% to Rs 270.32 crore, and net profit rose 31.0% to Rs 57.70 crore. Operating margin was 39.81% in FY26.
Debt to equity is 0.00 and return on equity is 12.94%. FY26 operating cash flow was Rs 266.88 crore against capital expenditure of Rs 95.15 crore. Concord Biotech paid a dividend of Rs 7.55 per share for FY26, a yield of 0.57%. At a P/E of 51.00 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: The P/E of 51.00 sits above the industry P/E of 37.59, so earnings delivery matters for the valuation.
ITC: Several Businesses Anchor the Roadmap
ITC’s roadmap rests on cigarettes, packaged foods, personal care, paperboards, hotels and agri products, with several businesses supporting steady cash flow.
Revenue grew from Rs 62,504.44 crore in FY22 to Rs 81,294.27 crore in FY26, a 30.1% rise, and FY26 revenue was 4.4% higher than FY25. FY26 net profit rose 4.9% to Rs 21,018.15 crore. Over four years, net profit rose from Rs 15,503.13 crore in FY22 to Rs 21,018.15 crore. In Q1 FY27, revenue grew 26.7% to Rs 30,179.01 crore. Operating margin was 33.18% in FY26.
Debt to equity is 0.03 and return on equity is 28.53%. FY26 operating cash flow was Rs 18,464.31 crore against capital expenditure of Rs 2,182.89 crore. At a P/E of 15.77 against an industry P/E of 34.85, the stock trades below its industry multiple.
What to watch: The P/E of 15.77 against an industry P/E of 34.85 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Best Pharma Brand, Fermentation Ingredient Maker and Hotels-To-Foods Group Stocks in India: Alkem vs Concord Biotech vs ITC on Key Financials
Among the best pharma brand, fermentation ingredient maker and hotels-to-foods group stocks in India, Alkem ranks second on return on equity and the lowest P/E; Concord Biotech leads on FY26 operating margin and the lowest debt to equity; ITC leads on Q1 FY27 revenue growth and return on equity. The table puts the numbers side by side.
| Metric | Alkem | Concord Biotech | ITC |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 15,295.62 | 1,107.25 | 81,294.27 |
| FY26 net profit (Rs Cr) | 2,353.13 | 259.23 | 21,018.15 |
| FY26 operating profit margin | 23.20% | 39.81% | 33.18% |
| Q1 FY27 revenue growth (YoY) | 11.0% | 24.2% | 26.7% |
| Return on equity | 16.66% | 12.94% | 28.53% |
| P/E ratio | 28.43 | 51.00 | 15.77 |
| Debt to equity | 0.15 | 0.00 | 0.03 |
| FY26 operating cash flow (Rs Cr) | 1,963.03 | 266.88 | 18,464.31 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Pharma Brand, Fermentation Ingredient Maker and Hotels-To-Foods Group Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen pharma brand, fermentation ingredient maker and hotels-to-foods group stocks and shortlist pharma brand, fermentation ingredient maker and hotels-to-foods group stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Pharma Brand, Fermentation Ingredient Maker and Hotels-To-Foods Group Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Alkem, Concord Biotech and ITC live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare and consumer stocks cover medicines, drug ingredients and a consumer conglomerate. Alkem ranks second on return on equity and the lowest P/E; Concord Biotech leads on FY26 operating margin and the lowest debt to equity; ITC leads on Q1 FY27 revenue growth and return on equity.
Across pharma brand, fermentation ingredient maker and hotels-to-foods group stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the pharma brand, fermentation ingredient maker and hotels-to-foods group stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Pharma Brand, Fermentation Ingredient Maker and Hotels-To-Foods Group Stocks
Which are the best pharma brand, fermentation ingredient maker and hotels-to-foods group stocks in India with a strong roadmap?
Ans. Alkem Laboratories, Concord Biotech and ITC stand out for their roadmaps in medicines, drug ingredients and a consumer conglomerate. Return on equity ranges from 12.94% to 28.53%.
Is Alkem Laboratories a good stock to buy now?
Ans. Alkem Laboratories has a debt to equity ratio of 0.15, a return on equity of 16.66% and a P/E of 28.43 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Alkem, Concord Biotech and ITC?
Ans. The P/E ratio is 28.43 for Alkem (industry 37.59), 51.00 for Concord Biotech (industry 37.59) and 15.77 for ITC (industry 34.85). Only Concord Biotech trades at or above the industry multiple.
Which of these pharma brand, fermentation ingredient maker and hotels-to-foods group stocks has the highest return on equity?
Ans. ITC has the highest return on equity at 28.53%, followed by Alkem Laboratories at 16.66% and Concord Biotech at 12.94%.
What are the risks of investing in pharma brand, fermentation ingredient maker and hotels-to-foods group stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did Alkem, Concord Biotech and ITC perform in Q1 FY27?
Ans. Alkem Laboratories reported revenue of Rs 3,892.90 crore, up 11.0% year on year. Concord Biotech reported revenue of Rs 270.32 crore, up 24.2% year on year, and net profit rose 31.0% to Rs 57.70 crore. ITC reported revenue of Rs 30,179.01 crore, up 26.7% year on year.
Do pharma brand, fermentation ingredient maker and hotels-to-foods group stocks pay dividends?
Ans. Alkem and Concord Biotech pay dividends. The dividend yield is 1.01% for Alkem and 0.57% for Concord Biotech, based on dividends declared for FY26.
How can I invest in pharma brand, fermentation ingredient maker and hotels-to-foods group stocks in India?
Ans. You can buy pharma brand, fermentation ingredient maker and hotels-to-foods group stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.